Pradaxa® (generic name: dabigatran etexilate mesylate) is an anticoagulant, a drug. It helps keep the blood from clotting, for individuals who have a specific heart rhythm problem called atrial fibrillation (AF).
Now, the FDA is investigating reports of uncontrollable bleeding and other serious bleeding events in AF patients who were being treated with Pradaxa®. A December 2011 Safety Announcement from the FDA notes, “At this time, FDA continues to believe that Pradaxa® provides an important health benefit when used as directed,” but many public health officials are concerned about the rise in Pradaxa®-related internal bleeding events and deaths.
The most prominent danger presented by Pradaxa® is the fact that there is no reversal agent for it. That is, unlike its predecessor drug warfarin (an anticoagulant medication), when a patient is bleeding too much (for whatever reason), there is no drug that can be administered to successfully stop the bleeding. He or she may continue bleeding or hemorrhaging until organ damage, coma, and/or death occur.
In fact, are several reports of deaths due to Pradaxa® treatment. For example, an elderly Utah man who took a minor fall in February 2012. Doctors found his brain bleeding uncontrollably. The man’s Pradaxa® treatment made efforts to stop the bleeding ineffective, and since there is no reversal agent for Pradaxa®’s effects, his bleeding continued, resulting in his death.
Although at this time the FDA states that the benefits of Pradaxa® when used appropriately outweigh the risks of this drug, there are other serious Pradaxa® side effects in addition to uncontrollable bleeding. These include:
A clinical study of 18,000 patients found that Pradaxa® treatment produced a 38 percent higher risk of heart attack compared to warfarin.
We represent people harmed by medications and can help you and your family pursue damages. Don’t delay! Call Clay! Our initial consultation is FREE! Our experienced staff members are here to help.